Fatty Liver Disease - Pipeline Review, H2 2014 th
On 30 September 2014
Summary Fatty Liver Disease - Pipeline Review, H2 2014, provides an overview of the Fatty Liver Diseases therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-fatty-liver-disease-pipeline-review-h2-2014-126952 Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope - The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industryspecific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Table of Content List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Fatty Liver Disease Overview 7 Therapeutics Development 8 Pipeline Products for Fatty Liver Disease - Overview 8 Pipeline Products for Fatty Liver Disease - Comparative Analysis 9 Fatty Liver Disease - Therapeutics under Development by Companies 10 Fatty Liver Disease - Therapeutics under Investigation by Universities/Institutes 12 Fatty Liver Disease - Pipeline Products Glance 13 Clinical Stage Products 13 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Early Stage Products 14 Fatty Liver Disease - Products under Development by Companies 15 Fatty Liver Disease - Products under Investigation by Universities/Institutes 16 Fatty Liver Disease - Companies Involved in Therapeutics Development 17 GW Pharmaceuticals plc 17 Protalix BioTherapeutics, Inc. 18 Genovate Biotechnology Co., LTD. 19 Huons Co., Ltd. 20 ChemoCentryx, Inc. 21 ACROVIS biostructures GmbH 22 Generon (Shanghai) Corporation Ltd. 23 Fatty Liver Disease - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 28 Assessment by Route of Administration 31 Assessment by Molecule Type 32 Drug Profiles 34 GWP-42003-P - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 etanercept biosimilar - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 F-652 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CCX-872 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecule to Inhibit Them1 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 SR-9238 - Drug Profile 39 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Product Description 39 Mechanism of Action 39 R&D Progress 39 cSN-50 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 CSN-501 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 PCBB-7 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 HU-002 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 E06-ScFV - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ACR-488 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Fatty Liver Disease - Recent Pipeline Updates 48 Fatty Liver Disease - Dormant Projects 50 Fatty Liver Disease - Product Development Milestones 51 Featured News & Press Releases 51 Jul 30, 2014: Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 51 Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 52 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 53 Mar 25, 2014: Galectin Therapeutics to Announce Results From First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease 54 Mar 03, 2014: Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial 55 Feb 26, 2014: Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease 55 Jan 08, 2014: Galectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity 56 Sep 10, 2013: Galectin Therapeutics Receives US Patent for Potential Ground-Breaking Treatment for Fatty Liver Disease 56 Aug 12, 2013: Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis 57 Jul 24, 2013: Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 60 Disclaimer 60 List Of Tables Number of Products under Development for Fatty Liver Disease, H2 2014 8 Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Fatty Liver Disease - Pipeline by GW Pharmaceuticals plc, H2 2014 17 Fatty Liver Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2014 18 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Fatty Liver Disease - Pipeline by Genovate Biotechnology Co., LTD., H2 2014 19 Fatty Liver Disease - Pipeline by Huons Co., Ltd., H2 2014 20 Fatty Liver Disease - Pipeline by ChemoCentryx, Inc., H2 2014 21 Fatty Liver Disease - Pipeline by ACROVIS biostructures GmbH, H2 2014 22 Fatty Liver Disease - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2014 23 Assessment by Monotherapy Products, H2 2014 24 Number of Products by Stage and Target, H2 2014 27 Number of Products by Stage and Mechanism of Action, H2 2014 30 Number of Products by Stage and Route of Administration, H2 2014 31 Number of Products by Stage and Molecule Type, H2 2014 33 Fatty Liver Disease Therapeutics - Recent Pipeline Updates, H2 2014 48 Fatty Liver Disease - Dormant Projects, H2 2014 50 List Of Figures Number of Products under Development for Fatty Liver Disease, H2 2014 8 Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Products, H2 2014 14 Assessment by Monotherapy Products, H2 2014 24 Number of Products by Top 10 Target, H2 2014 25 Number of Products by Stage and Top 10 Target, H2 2014 26 Number of Products by Top 10 Mechanism of Action, H2 2014 28 Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 29 Number of Products by Stage and Top 10 Route of Administration, H2 2014 31 Number of Products by Top 10 Molecule Type, H2 2014 32 Number of Products by Stage and Top 10 Molecule Type, H2 2014 33
Report Price: Licence Type
Price
$ 2000
Site Licence
$ 4000
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Enterprise Wide Licence
$ 6000
Related Reports: India Probiotic Market Forecast and Opportunities, 2019 Kaketsuken K.K. - Product Pipeline Review - 2014 Orphagen Pharmaceuticals, Inc. - Product Pipeline Review - 2014 NGM Biopharmaceuticals, Inc. - Product Pipeline Review - 2014 S.L.A. Pharma AG - Product Pipeline Review - 2014 Quintessence Biosciences, Inc. - Product Pipeline Review - 2014 Presidio Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Vaxeal Holding SA - Product Pipeline Review - 2014 Vaxil Bio Therapeutics Ltd. - Product Pipeline Review - 2014 TSRL, Inc. - Product Pipeline Review - 2014
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Fatty Liver Disease - Pipeline Review, H2 2014 http://www.jsbmarketresearch.com/healthcare-medical/r-fatty-liver-diseasepipeline-review-h2-2014-126952 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/